Holen Sie sich die Stockscreener-App
10.12
0.10%
-0.01
Vorhandelsmarkt:
10.12
Schlusskurs vom Vortag:
$10.13
Offen:
$10.16
24-Stunden-Volumen:
2.10M
Relative Volume:
1.33
Marktkapitalisierung:
$387.33M
Einnahmen:
$127.70M
Nettoeinkommen (Verlust:
$-121.25M
KGV:
-3.2127
EPS:
-3.15
Netto-Cashflow:
$-120.32M
1W Leistung:
-1.84%
1M Leistung:
+1.61%
6M Leistung:
+31.26%
1J Leistung:
-38.69%
1-Tages-Spanne:
$10.10
$10.19
1-Wochen-Bereich:
$10.10
$10.47
52-Wochen-Spanne:
$4.80
$18.13
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Firmenname
Iteos Therapeutics Inc
Sektor
Branche
Telefon
857-204-4583
Adresse
321 ARSENAL STREET, WATERTOWN
Vergleichen Sie ITOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.12 | 394.60M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-05-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-13 | Eingeleitet | Wells Fargo | Overweight |
| 2021-05-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-18 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Iteos Therapeutics Inc Aktie (ITOS) Neueste Nachrichten
Assessing the Fairness of iTeos Therapeutics' $10.047-per-Share Acquisition Offer: A Valuation Deep Dive - AInvest
ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc.ITOS - The Globe and Mail
Is iTeos Therapeutics Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
iTeos Therapeutics accepts takeover bid from Concentra - The Pharma Letter
Concentra buys beleaguered iTeos at slight discount - PharmaLive
iTeos Therapeutics stock price target lowered to $10 at Leerink Partners - Investing.com Canada
What analysts say about iTeos Therapeutics Inc. stockMassive profits - jammulinksnews.com
What drives iTeos Therapeutics Inc. stock priceFree Market Volatility Navigation Tips - jammulinksnews.com
iTeos Therapeutics (NASDAQ:ITOS) Given Outperform Rating at Wedbush - Defense World
Securities Law Risks in Biotech M&A: A Closer Look at iTeos Therapeutics' Proposed Acquisition - AInvest
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders - GlobeNewswire Inc.
Rowley Law PLLC Investigates iTeos Therapeutics Acquisition for Securities Law Violations - AInvest
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of ITeos Therapeutics, Inc. - 富途牛牛
Navigating ITOS Stock: ITeos Therapeutics Inc Journey - investchronicle.com
iTeos Therapeutics To Be Acquired by Concentra Biosciences - citybiz
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders - The Globe and Mail
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - Stock Titan
Concentra To Acquire ITeos - Nasdaq
The Strategic Rationale and Valuation Implications of Concentra Biosciences' Acquisition of iTeos Therapeutics - AInvest
iTeos Therapeutics, Inc. Enters Merger Agreement with Concentra Biosciences, LLC for $10.047 per Share Acquisition - Quiver Quantitative
iTeos Therapeutics Enters into Agreement to Be Acquired by - GlobeNewswire
iTeos Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - Informazione.it
What risks could impact iTeos Therapeutics Inc. stock performanceFree Stock Index Interpretation - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
GSK and Iteos Therapeutics’ Promising Phase 3 Study on NSCLC Treatment - TipRanks
How iTeos Therapeutics Inc. stock performs during market volatilityFree Stock Market Expert Consultation - Newser
What makes iTeos Therapeutics Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why iTeos Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Query - Newser
GSK and iTeos Therapeutics Advance Phase 3 NSCLC Study with Belrestotug and Dostarlimab - TipRanks
iTeos Therapeutics (ITOS): An Example of Biotech Liquidations - MSN
iTeos Therapeutics Stock Jumps Following Operational Closure Announcement - MSN
(ITOS) Technical Data - news.stocktradersdaily.com
iTeos Therapeutics CEO Michel Detheux sells $1.59m in stock By Investing.com - Investing.com Nigeria
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Exchange Traded Concepts LLC Acquires 3,468 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
iTeos Therapeutics Holds Annual Stockholders Meeting - TipRanks
Finanzdaten der Iteos Therapeutics Inc-Aktie (ITOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):